The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Takeda will seek an external partner to leverage its cell therapy platform technologies
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Subscribe To Our Newsletter & Stay Updated
